Twenty-seven percent of NDCs are sourced from high risk areas, or non-TAA compliant suppliers, and 27% are from very high-risk sources, or complete dependence on manufacturers in China and unknown countries.
The Department of Defense said a fourth of NDCs are most secure because multiple domestic manufacturers produce the active pharmaceutical ingredients, and 21% are moderately secure or moderately at risk. The military’s report equates to about 10% of the total U.S. marketplace.
Here’s what the Department of Defense found:
- 25% of APIs for medications, or 3,272 NDCs, are sourced in the U.S.
- 3%, or 345 NDCs, are sourced in Canada and Mexico
- 18%, or 2,373 NDCs, are sourced from TAA-compliant countries outside North America
- 26%, or 3,349 NDCs, are sourced from India
- 5%, or 650 NDCs, are sourced from China, a non-TAA compliant country
- 1%, or 180 NDCs, are sourced from non-TAA compliant countries, including Brazil, Jordan, Malaysia and Thailand
- 22%, or 2,820 NDCs, are sourced from unknown countries
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.